{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T22:15:19Z","timestamp":1788214519858,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd015530","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:00:00Z","timestamp":1747785600000}}],"reference-count":161,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd015530.pub2","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T07:07:42Z","timestamp":1747811262000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Vaccines for preventing infections in adults with haematological malignancies"],"prefix":"10.1002","volume":"2025","author":[{"given":"Ana-Mihaela","family":"Zorger","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK, Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Hirsch","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK, Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandy","family":"Baumann","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK, Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merit","family":"Feldmann","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK, Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J","family":"Br\u00f6ckelmann","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"},{"name":"Max-Planck Institute for the Biology of Ageing; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibylle","family":"Mellinghoff","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD); Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"},{"name":"German Centre for Infection Research (DZIF); partner site Bonn-Cologne Germany"},{"name":"Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD); University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Monsef","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK, Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK, Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Kreuzberger","sequence":"additional","affiliation":[{"name":"Cochrane Evidence Synthesis Unit Germany\/UK, Cochrane Haematology, Institute of Public Health; Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"e35574","DOI":"10.1002\/cncr.35574","article-title":"Influenza vaccine effectiveness in immunocompromised patients with cancer: a Danish nationwide register-based cohort study","volume":"131","author":"Amdisen","year":"2024","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0002|cit2","unstructured":"Amdisen L Subgroup outcome data for population with haematological malignancies [personal communication] Email to: A-M Zorger"},{"issue":"11","key":"10.1002\/14651858.CD015530.pub2-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41408-022-00749-8","article-title":"Breakthrough infections in MPN-COVID vaccinated patients","volume":"12","author":"Barbui","year":"2022","journal-title":"Blood Cancer Journal"},{"issue":"Supplement 1","key":"10.1002\/14651858.CD015530.pub2-BIB0004|cit4","doi-asserted-by":"publisher","first-page":"6815\u20138","DOI":"10.1182\/blood-2022-158902","article-title":"Protection against breakthrough delta\/omicron variants in vaccinated patients with myeloproliferative neoplasms (MPN)","volume":"140","author":"Barbui","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1002\/14651858.CD015530.pub2-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1182\/blood.V128.22.2139.2139","article-title":"Lower rates of influenza infection following two dose series of high dose vaccination in plasma cell disorders: results of a randomized, double-blind, placebo-assisted clinical trial","volume":"128","author":"Branagan","year":"2016","journal-title":"Blood"},{"issue":"9","key":"10.1002\/14651858.CD015530.pub2-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"Dagnew","year":"2019","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0007|cit7","doi-asserted-by":"publisher","first-page":"9-10","DOI":"10.1093\/ofid\/ofy209.019","article-title":"Immunogenicity, safety, and post-hoc efficacy assessment of the adjuvanted recombinant zoster vaccine in adults with hematologic malignancies: a phase 3, randomized clinical trial","volume":"5","author":"Dagnew","year":"2018","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0008|cit8","unstructured":"Study to check safety and immune response of GSK Biologicals' Herpes Zoster vaccine GSK1437173A in adults aged 18 years and older with blood cancers https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2012-003438-18-SE"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0009|cit9","unstructured":"Study to assess the safety and immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ\/su) vaccine in adults aged 18 years and older with blood cancers https:\/\/clinicaltrials.gov\/study\/NCT01767467"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Oostvogels L Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults with hematologic malignancies: a phase III, randomized clinical trial Open Forum Infectious Diseases 2017 S415","DOI":"10.1093\/ofid\/ofx163.1040"},{"issue":"10","key":"10.1002\/14651858.CD015530.pub2-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"e337","DOI":"10.1016\/S1473-3099%2819%2930469-4","article-title":"Correction to safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial (The Lancet Infectious Diseases (2019) 19(9) (1001-1012), (S147330991930310X), (10.1016\/S1473-3099(19)30310-X))","volume":"19","year":"2019","journal-title":"Lancet Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD015530.pub2-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"ofaa172","DOI":"10.1093\/ofid\/ofaa172","article-title":"Immunogenicity of inactivated varicella zoster vaccine in autologous hematopoietic stem cell transplant recipients and patients with solid or hematologic cancer","volume":"7","author":"Boeckh","year":"2020","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0013|cit13","unstructured":"A phase III randomized, placebo-controlled, clinical trial to study the safety and efficacy of V212 in adult patients with solid tumor or hematologic malignancy https:\/\/clinicaltrials.gov\/study\/NCT01767467"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0014|cit14","unstructured":"A phase III randomized, placebo-controlled, clinical trial to study the safety and efficacy of V212 in adult patients with solid tumor or hematologic malignancy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2010-023156-89-AT"},{"issue":"9","key":"10.1002\/14651858.CD015530.pub2-BIB0015|cit15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/S1473-3099(19)30310-X","article-title":"Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial","volume":"19","author":"Mullane","year":"2019","journal-title":"Lancet Infectious Diseases"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0016|cit16","unstructured":"A study to evaluate the safety and efficacy of inactivated varicella-zoster vaccine (VZV) as a preventative treatment for herpes zoster (HZ) and HZ-related complications in adult participants with solid tumor or hematologic malignancy (V212-011) https:\/\/clinicaltrials.gov\/study\/NCT01254630"},{"issue":"40","key":"10.1002\/14651858.CD015530.pub2-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"5798","DOI":"10.1016\/j.vaccine.2022.08.036","article-title":"Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults","volume":"40","author":"Fraiman","year":"2022","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"issue":"27","key":"10.1002\/14651858.CD015530.pub2-BIB0019|cit19","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD015530.pub2-BIB0020|cit20","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 5","key":"10.1002\/14651858.CD015530.pub2-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.annonc.2021.08.1551","article-title":"1558O COVID-19 vaccine in participants (ptcpts) with cancer: subgroup analysis of efficacy\/safety from a global phase III randomized trial of the BNT162b2 (tozinameran) mRNA vaccine","volume":"32","author":"Thomas","year":"2021","journal-title":"Annals of Oncology"},{"issue":"10","key":"10.1002\/14651858.CD015530.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1016\/j.vaccine.2021.12.046","article-title":"Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial","volume":"40","author":"Thomas","year":"2022","journal-title":"Vaccine"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0023|cit23","unstructured":"COVID-19 vaccine boost to enhance immunity in healthy adults aged 18-65 (The Booster Study) https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=383572&isReview=true"},{"issue":"11","key":"10.1002\/14651858.CD015530.pub2-BIB0024|cit24","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1007\/s12149-021-01675-8","article-title":"Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients","volume":"35","author":"Advani","year":"2021","journal-title":"Annals of Nuclear Medicine"},{"issue":"10","key":"10.1002\/14651858.CD015530.pub2-BIB0025|cit25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.3390\/vaccines12101163","article-title":"SARS-CoV-2 vaccination in patients with cancer and COVID-19 in Mexico","volume":"12","author":"Barrientos-Flores","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0026|cit26","unstructured":"A phase II study to evaluate safety and efficacy to a third vaccination with an mRNA or vector vaccine in patients under immunosuppressive therapy no or reduced responds to standard mRNA SARS-CoV-2 (Covid-19) vaccination https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=EUCTR2021-002693-10-AT"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0027|cit27","unstructured":"Investigating COVID-19 infection in patients with acute myeloid leukaemia (AML) undergoing chemotherapy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=ISRCTN16865769"},{"issue":"15 SUPPL. 1","key":"10.1002\/14651858.CD015530.pub2-BIB0028|cit28","first-page":"1375","article-title":"Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in adults with solid tumor malignancy (STM)","volume":"29","author":"Mullane","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1002\/14651858.CD015530.pub2-BIB0029|cit29","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1093\/infdis\/jit344","article-title":"Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adults","volume":"208","author":"Mullane","year":"2013","journal-title":"Journal of Infectious Diseases"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0030|cit30","unstructured":"A study of an investigational V212\/heat-treated varicella-zoster virus (VZV) vaccine in immunocompromised adults (V212-002) https:\/\/clinicaltrials.gov\/show\/NCT00535236"},{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0031|cit31","doi-asserted-by":"publisher","first-page":"e3240","DOI":"10.1002\/hon.3240","article-title":"Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: results from the EPICOVIDEHA registry","volume":"42","author":"Musto","year":"2023","journal-title":"Hematological Oncology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0032|cit32","unstructured":"Efficacy of COVID-19 vaccination in patients treated with anti-CD20 for follicular lymphoma or mantle cell lymphoma (VAXIMAB) https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04918940"},{"issue":"10","key":"10.1002\/14651858.CD015530.pub2-BIB0033|cit33","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1038\/s41416-022-01952-x","article-title":"Natural immunity to SARS-CoV-2 and breakthrough infections in vaccinated and unvaccinated patients with cancer","volume":"127","author":"Cortellini","year":"2022","journal-title":"British Journal of Cancer"},{"issue":"16","key":"10.1002\/14651858.CD015530.pub2-BIB0034|cit34","doi-asserted-by":"publisher","first-page":"e18725","DOI":"10.1200\/JCO.2022.40.16_suppl.e18725","article-title":"Clinical effectiveness of SARS-CoV-2 vaccines and booster doses in patients with cancer: an analysis from the European OnCovid registry","volume":"40","author":"Pinato","year":"2022","journal-title":"Journal of Clinial Oncology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0035|cit35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejca.2022.04.036","article-title":"Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer","volume":"171","author":"Pinato","year":"2022","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD015530.pub2-BIB0036|cit36","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/cid\/ciae192","article-title":"COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials","volume":"79","author":"Sherman","year":"2024","journal-title":"Clinical Infectious Diseases"},{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0037|cit37","doi-asserted-by":"publisher","first-page":"5362","DOI":"10.1038\/s41467-022-33036-y","article-title":"Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial","volume":"13","author":"Mrak","year":"2022","journal-title":"Nature Communications"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0038|cit38","unstructured":"Pneumococcal vaccination of multiple myeloma patients on novel agents https:\/\/clinicaltrials.gov\/show\/NCT03619252"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0039|cit39","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1097\/HS9.0000000000000404","article-title":"How to prevent pneumonias in patients with multiple myeloma on novel agents: the new regimen of pneumococcal vaccination","volume":"4 (Supplement 1","author":"Stoma","year":"2020","journal-title":"Hemasphere"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0040|cit40","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.ijid.2020.09.1232","article-title":"Efficacy of pneumococcal vaccination in patients with multiple myeloma receiving novel agents: results of a prospective clinical study","volume":"101 (Supplement","author":"Stoma","year":"2020","journal-title":"International Journal of Infectious Diseases"},{"issue":"30","key":"10.1002\/14651858.CD015530.pub2-BIB0041|cit41","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1016\/j.vaccine.2020.05.024","article-title":"Clinical efficacy of pneumococcal vaccination in multiple myeloma patients on novel agents: results of a prospective clinical study","volume":"38","author":"Stoma","year":"2020","journal-title":"Vaccine"},{"issue":"11","key":"10.1002\/14651858.CD015530.pub2-BIB0042|cit42","doi-asserted-by":"publisher","first-page":"e4269","DOI":"10.1093\/cid\/ciaa1711","article-title":"A randomized trial of two 2-dose influenza vaccination strategies for patients following autologous hematopoietic stem cell transplantation","volume":"73","author":"Teh","year":"2021","journal-title":"Clinical Infectious Diseases"},{"issue":"7","key":"10.1002\/14651858.CD015530.pub2-BIB0043|cit43","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3109\/10428194.2012.742524","article-title":"Evaluation of 2009 pandemic H1N1 influenza vaccination in adults with lymphoid malignancies receiving chemotherapy or following autologous stem cell transplant 322","volume":"54","author":"Villa","year":"2013","journal-title":"Leukemia & Lymphoma"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0044|cit44","unstructured":"Villa D Population details [personal communication] Email to: A-M Zorger"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0045|cit45","unstructured":"Awan FT Thangavadivel S Weiss D Wei L Woyach JA Rogers KA A phase 2 trial of early intervention with ibrutinib in patients with asymptomatic, high-risk CLL Blood 2017 130 1748 10.1182\/blood.V130.Suppl_1.1748.1748"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0046|cit46","doi-asserted-by":"crossref","unstructured":"Woyach J Thangavadivel S Weiss D Wei L McLaughlin E Rogers K Final results of a phase 2 trial of early intervention ibrutinib with vaccinations in patients with asymptomatic, high-risk CLL Blood 2019 134 (Supplement 1) 1759 10.1182\/blood-2019-131099","DOI":"10.1182\/blood-2019-131099"},{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0047|cit47","doi-asserted-by":"publisher","first-page":"e051254","DOI":"10.1136\/bmjopen-2021-051254","article-title":"The Canadian national vaccine safety network: surveillance of adverse events following immunisation among individuals immunised with the COVID-19 vaccine, a cohort study in Canada","volume":"12","author":"Bettinger","year":"2022","journal-title":"British Medical Journal Open"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0048|cit48","unstructured":"Evaluation of pneumococcal conjugate vaccine (Prevenar) in patients with myeloma and chronic lymphocytic leukaemia - pneumococcal conjugate vaccination in haematology patients: version 1 https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2005-003761-16\/GB"},{"issue":"6","key":"10.1002\/14651858.CD015530.pub2-BIB0049|cit49","doi-asserted-by":"publisher","first-page":"e339","DOI":"10.1016\/S2665-9913(24)00065-1","article-title":"Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open label, multicentre, randomised, controlled, phase 3 trial","volume":"6","author":"Goodyear","year":"2024","journal-title":"Lancet Rheumatology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0050|cit50","unstructured":"Randomised trial optimising COVID-19 vaccination in patients with chronic health conditions and a poor response to standard vaccination https:\/\/www.isrctn.com\/ISRCTN15354495"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0051|cit51","unstructured":"Vaccination response in immuno-compromised host 2 https:\/\/www.isrctn.com\/ISRCTN15762138"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0052|cit52","unstructured":"A study on the long-term efficacy, safety and persistence of immune response of a vaccine against herpes zoster in older adults https:\/\/rctportal.mhlw.go.jp\/detail\/jr?trial_id=jRCT1080223260"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0053|cit53","unstructured":"Efficacy of sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in the adults with immunocompromising conditions -A double blind randomized controlled trial- - CPI study [sic] https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCT1090220246"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0054|cit54","unstructured":"Efficacy of sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in the adults with immunocompromising conditions -A double blind randomized controlled trial- - CPI study [sic] https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=JPRN-jRCTs031180147"},{"issue":"7_Supplement","key":"10.1002\/14651858.CD015530.pub2-BIB0055|cit55","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1158\/1538-7445.AM2023-798","article-title":"SeroNet pooling project of immunocompromised populations","volume":"83","author":"Kazemain","year":"2023","journal-title":"Cancer Research"},{"issue":"5","key":"10.1002\/14651858.CD015530.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1053\/j.seminoncol.2022.07.005","article-title":"Influence of cancer on COVID-19 incidence, outcomes, and vaccine effectiveness: a prospective cohort study of U.S. veterans","volume":"49","author":"Leuva","year":"2022","journal-title":"Seminars in Oncology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0057|cit57","unstructured":"Leuva H Outcome data [personal communication] Email to C Hirsch"},{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0058|cit58","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1111\/j.1365-2141.2005.05582.x","article-title":"Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study","volume":"130","author":"Ljungman","year":"2005","journal-title":"British Journal of Haematology"},{"issue":"11","key":"10.1002\/14651858.CD015530.pub2-BIB0059|cit59","doi-asserted-by":"publisher","first-page":"828","DOI":"10.7326\/0003-4819-123-11-199512010-00003","article-title":"Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease","volume":"123","author":"Molrine","year":"1995","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0060|cit60","first-page":"504","article-title":"Vaccination against influenza in multiple myeloma","volume":"97","author":"Musto","year":"1997","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0061|cit61","unstructured":"Trivalent baculovirus-expressed Influenza HA vaccine in adults with non-Hodgkin's B-cell lymphoma https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00307177"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0062|cit62","unstructured":"Influenza vaccination in patients receiving antineoplastic therapy for non-Hodgkin's lymphoma https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00307710"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0063|cit63","unstructured":"Evaluation of influenza H1N1 vaccine in adults with lymphoid malignancies on chemotherapy https:\/\/clinicaltrials.gov\/show\/NCT01016548"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0064|cit64","unstructured":"Study of high-dose influenza vaccine efficacy by repeated dosing in gammopathy patients https:\/\/clinicaltrials.gov\/study\/NCT02566265"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0065|cit65","unstructured":"Influenza vaccination for flu prevention in patients with plasma cell disorders https:\/\/clinicaltrials.gov\/study\/NCT04080531"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0066|cit66","unstructured":"Immune response to pandemische influenza A\/H1N1 vaccination in the immunocompromised https:\/\/onderzoekmetmensen.nl\/en\/node\/32477\/pdf"},{"issue":"3","key":"10.1002\/14651858.CD015530.pub2-BIB0067|cit67","doi-asserted-by":"publisher","first-page":"231","DOI":"10.4274\/tjh.2015.0079","article-title":"A randomized study comparing the efficacy of three hepatitis B vaccine induction regimens in adult patients with hematological malignancies","volume":"33","author":"Ozkurt","year":"2016","journal-title":"Turkish Journal of Haematology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0068|cit68","unstructured":"A phase III randomized, placebo-controlled, clinical trial to study the safety and efficacy of V212 in adult patients with solid tumor or hematologic malignancy https:\/\/trialsearch.who.int\/Trial2.aspx?TrialID=PER-014-11"},{"issue":"10","key":"10.1002\/14651858.CD015530.pub2-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11101528","article-title":"Immunogenicity and safety of MF59-adjuvanted quadrivalent influenza vaccine compared with a nonadjuvanted, quadrivalent influenza vaccine in adults 50\u201364 years of age","volume":"11","author":"Poder","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"10.1002\/14651858.CD015530.pub2-BIB0070|cit70","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s12664-015-0595-y","article-title":"The efficacy of accelerated, multiple, double-dose hepatitis B vaccine against hepatitis B virus infection in cancer patients receiving chemotherapy","volume":"34","author":"Sodhi","year":"2015","journal-title":"Indian Journal of Gastroenterology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0071|cit71","doi-asserted-by":"publisher","first-page":"S445-46","DOI":"10.1093\/ofid\/ofy210.1272","article-title":"Doses of 13-valent conjugated pneumococcal vaccine (PCV13) for patients with multiple myeloma (MM)","volume":"5","author":"Sun","year":"2018","journal-title":"Open Forum Infectious Diseases"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0072|cit72","unstructured":"Pneumococcal vaccine in untreated CLL patients https:\/\/clinicalTrials.gov\/show\/NCT01892618"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0073|cit73","first-page":"331","article-title":"Conjugated pneumococcal vaccine triggers a better immune response than polysaccharide pneumococcal vaccine in patients with chronic lymphocytic leukemia a randomized study by the Swedish CLL group","volume":"102","author":"Svensson","year":"2017","journal-title":"Haematologica"},{"issue":"25","key":"10.1002\/14651858.CD015530.pub2-BIB0074|cit74","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.1016\/j.vaccine.2018.05.012","article-title":"Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia a randomized study by the Swedish CLL group","volume":"36","author":"Svensson","year":"2018","journal-title":"Vaccine"},{"issue":"23","key":"10.1002\/14651858.CD015530.pub2-BIB0075|cit75","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1158\/1078-0432.CCR-20-1280","article-title":"Early intervention with lenalidomide in patients with high-risk chronic lymphocytic leukemia","volume":"26","author":"Thangavadivel","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"22","key":"10.1002\/14651858.CD015530.pub2-BIB0076|cit76","doi-asserted-by":"publisher","first-page":"4028","DOI":"10.1002\/cncr.28351","article-title":"Clinical effectiveness of seasonal influenza vaccine among adult cancer patients","volume":"119","author":"Vinograd","year":"2013","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0077|cit77","unstructured":"Influenza vaccination strategies in haematological cancers https:\/\/anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12622000454774"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0078|cit78","unstructured":"Response to influenza vaccination in lymphoma patients treated with CHOP and rituximab (RITUXIVAC) https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2012-005713-39"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0079|cit79","unstructured":"Immunosuppression and COVID-19 boosters https:\/\/clinicaltrials.gov\/study\/NCT05415267"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0080|cit80","unstructured":"Anti-pneumococcal vaccine strategy in patients with chronic lymphocytic leukemia https:\/\/clinicaltrials.gov\/study\/NCT05417165"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0081|cit81","unstructured":"Bayside Health Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): an adaptive randomised controlled clinical trial https:\/\/clinicaltrials.gov\/study\/NCT05556720"},{"issue":"485","key":"10.1002\/14651858.CD015530.pub2-BIB0082|cit82","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-024-08315-2","article-title":"Bringing optimised COVID-19 vaccine schedules to immunocompromised populations (BOOST-IC): study protocol for an adaptive randomised controlled clinical trial","volume":"25","author":"Griffin","year":"2024","journal-title":"Trials"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0083|cit83","unstructured":"Vaccines and COVID-19 in multiple myeloma https:\/\/clinicaltrials.gov\/study\/NCT05831787"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0084|cit84","unstructured":"Response to vaccination in patients with cancer of the lymph nodes who are treated with chemotherapy https:\/\/www.onderzoekmetmensen.nl\/en\/trial\/27098"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0085|cit85","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/978-3-319-35153-7_29","volume-title":"Pathology and Epidemiology of Cancer","author":"Batista","year":"2017"},{"issue":"2","key":"10.1002\/14651858.CD015530.pub2-BIB0086|cit86","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008983.pub3","article-title":"Influenza vaccines in immunosuppressed adults with cancer","author":"Bitterman","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD015530.pub2-BIB0087|cit87","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015551","article-title":"Vaccines for the prevention of infections in adults with solid tumors","author":"Bora","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0088|cit88","unstructured":"Boutron I Page MJ Higgins JP Altman DG Lundh A Hr\u00f3bjartsson A Chapter 7: Considering bias and conflicts of interest among the included studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available from https:\/\/training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD015530.pub2-BIB0089|cit89","doi-asserted-by":"publisher","first-page":"437","DOI":"10.3949\/ccjm.91a.24019","article-title":"Preventing herpes zoster in immunocompromised patients: current concepts","volume":"91","author":"Calabrese","year":"2024","journal-title":"Celeveland Clinic Journal of Medicine"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0090|cit90","unstructured":"Cancer Research UK Cancer incidence for common cancers: the 20 most common cancers, UK, 2016-2018 https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/incidence\/common-cancers-compared"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0091|cit91","unstructured":"Advisory Committee on Immunization Practices (ACIP) General best practice guidelines for immunization: best practices guidance of the Advisory Committee on Immunization Practices (ACIP) https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/interim-considerations-us.html#immunocompromised"},{"issue":"3","key":"10.1002\/14651858.CD015530.pub2-BIB0092|cit92","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jama.1965.03090020019005","article-title":"Causes of death in adults with acute leukemia","volume":"55","author":"Chang","year":"1976","journal-title":"Medicine"},{"issue":"5","key":"10.1002\/14651858.CD015530.pub2-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1097\/01.md.0000232560.22098.4e","article-title":"Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center","volume":"85","author":"Chemaly","year":"2006","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1002\/14651858.CD015530.pub2-BIB0094|cit94","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006505.pub2","article-title":"Vaccines for prophylaxis of viral infections in patients with hematological malignancies","author":"Cheuk","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0095|cit95","doi-asserted-by":"publisher","first-page":"73","DOI":"10.4103\/0974-777X.77299","article-title":"Fundamentals of Vaccine Immunology","volume":"3","author":"Clem","journal-title":"Journal of Global Infectious Diseases"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0096|cit96","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jclinepi.2019.04.002","article-title":"Established search filters may miss studies when identifying randomized controlled trials","volume":"112","author":"Cooper","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0097|cit97","unstructured":"Covidence Veritas Health Innovation 2023"},{"issue":"13","key":"10.1002\/14651858.CD015530.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/cncr.31551","article-title":"Annual report to the nation on the status of cancer, part I: national cancer statistics","volume":"124","author":"Cronin","year":"2018","journal-title":"Cancer"},{"issue":"10226","key":"10.1002\/14651858.CD015530.pub2-BIB0099|cit99","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/S0140-6736(19)32007-0","article-title":"Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study","volume":"395","author":"Dagenais","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD015530.pub2-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"153","DOI":"10.31662\/jmaj.2023-0171","article-title":"Efficacy of COVID-19 vaccines in patients with hematological malignancy compared to healthy controls: a systematic review and meta-analysis","volume":"7","author":"Das Barshan","year":"2024","journal-title":"JMA Journal"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0101|cit101","doi-asserted-by":"publisher","first-page":"f2304","DOI":"10.1136\/bmj.f2304","article-title":"Influence of trial sample size on treatment effect estimates: meta-epidemiological study","volume":"346","author":"Dechartres","year":"2013","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0102|cit102","unstructured":"Deeks JJ Higgins JPT Altman DG McKenzie JE Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available from https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0103|cit103","unstructured":"Roadmap 2019 for research into cancer and blood diseases in Germany of the German Society for Hematology and Medical Oncology Available at https:\/\/www.dgho.de\/publikationen\/stellungnahmen\/klinische-forschung\/forschungs-roadmap\/dgho_forschungs-roadmap_20190313.pdf\/view"},{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0104|cit104","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/2643-3230.BCD-20-0177","article-title":"Viral immunity and vaccines in hematologic malignancies: implications for COVID-19","volume":"2","author":"Dhodapkar","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0105|cit105","unstructured":"Eldridge S Campbell M Campbell M Dahota A Giraudeau B Reeves B Revised Cochrane risk of bias tool for randomized trials (RoB 2.0). Additional considerations for cluster-randomized trials (RoB 2 CRT) Available at drive.google.com\/file\/d\/1yDQtDkrp68_8kJiIUdbongK99sx7RFI-\/view"},{"issue":"3","key":"10.1002\/14651858.CD015530.pub2-BIB0106|cit106","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.currproblcancer.2007.01.005","article-title":"Racial differences in the incidence and outcomes for patients with hematological malignancies","volume":"31","author":"Flowers","year":"2007","journal-title":"Current Problems in Cancer"},{"issue":"2","key":"10.1002\/14651858.CD015530.pub2-BIB0107|cit107","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.idc.2019.02.004","article-title":"Respiratory virus infections of the stem cell transplant recipient and the hematologic malignancy patient","volume":"33","author":"Fontana","year":"2019","journal-title":"Infectious Disease Clinics of North America"},{"issue":"6","key":"10.1002\/14651858.CD015530.pub2-BIB0108|cit108","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1016\/j.cell.2021.02.030","article-title":"Novel approaches for vaccine development","volume":"184","author":"Gebre","year":"2021","journal-title":"Cell"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0109|cit109","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ejca.2021.01.033","article-title":"COVID-19 guideline panel of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). 2021 update of the AGIHO guideline on evidence-based management of COVID-19 in patients with cancer regarding diagnostics, viral shedding, vaccination and therapy","volume":"147","author":"Giesen","year":"2021","journal-title":"European Journal of Cancer"},{"issue":"3","key":"10.1002\/14651858.CD015530.pub2-BIB0110|cit110","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/hir.12269","article-title":"Translating the Cochrane EMBASE RCT filter from the Ovid interface to Embase.com: a case study","volume":"36","author":"Glanville","year":"2019","journal-title":"Health Information & Libraries Journal"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0111|cit111","unstructured":"Immunization of immunocompromised persons: Canadian immunization guide Available at https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-3-vaccination-specific-populations\/page-8-immunization-immunocompromised-persons.html#a15"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0112|cit112","unstructured":"GRADEpro GDT McMaster University (developed by Evidence Prime) 2020"},{"issue":"2","key":"10.1002\/14651858.CD015530.pub2-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1001\/jama.1965.03090020019005","article-title":"Causes of death in acute leukemia: a ten-year study of 414 patients from 1954-1963","volume":"193","author":"Hersh","year":"1965","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0114|cit114","unstructured":"Higgins JPT Eldridge S Li T Chapter 23: Including variants on randomized trials (chapter last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available at https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0115|cit115","unstructured":"Higgins JP Savovi\u0107 J Page MJ Elbers RG Sterne JAC Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available at https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0116|cit116","unstructured":"Higgins J Li T Altman D Curtin F Senn S Revised Cochrane risk of bias tool for randomized trials (RoB 2) - additional considerations for crossover trials; March 2021 Available at https:\/\/drive.google.com\/file\/d\/11LFgCuDpWk5-BvBNbHtNzbJv5-qVpTWb\/view"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0117|cit117","unstructured":"Higgins JP Li T Deeks JJ Chapter 6: Choosing effect measures and computing estimates of effect (chapter last updated August 2023). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available at https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0118|cit118","unstructured":"Higgins JPT Thomas J Chandler J Cumpston M Li T Page MJ Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available at https:\/\/training.cochrane.org\/handbook"},{"issue":"4","key":"10.1002\/14651858.CD015530.pub2-BIB0119|cit119","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015551.pub2","article-title":"Vaccines for preventing infections in adults with solid tumours","author":"Hirsch","year":"2025","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0120|cit120","doi-asserted-by":"crossref","unstructured":"Ioannidis JP Why most published research findings are false PLoS Medicine 2005 2 8 10.1371\/journal.pmed.1004085","DOI":"10.1371\/journal.pmed.0020124"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0121|cit121","doi-asserted-by":"publisher","first-page":"114000","DOI":"10.1016\/j.addr.2021.114000","article-title":"Messenger RNA-based vaccines: past, present, and future directions in the context of the COVID-19 pandemic","volume":"179","author":"Jain","year":"2021","journal-title":"Advanced Drug Delivery Reviews"},{"issue":"14","key":"10.1002\/14651858.CD015530.pub2-BIB0122|cit122","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.24.00032","article-title":"Vaccination of adults with cancer: ASCO guideline","volume":"42","author":"Kamboj","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0123|cit123","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45953-1","article-title":"Persistence in risk and effect of COVID-19 vaccination on long-term health consequences after SARS-CoV-2 infection","volume":"15","author":"Lam","year":"2024","journal-title":"Nature Communications"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0124|cit124","unstructured":"Lefebvre C Glanville J Briscoe S Featherstone R Littlewood A Marshall C Chapter 4: Searching for and selecting studies. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022). Cochrane, 2022 Available at https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0125|cit125","unstructured":"McGill COVID19 Vaccine Tracker Team COVID-19 vaccine tracker https:\/\/covid19.trackvaccines.org\/"},{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0126|cit126","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Research Synthesis Methods"},{"issue":"6","key":"10.1002\/14651858.CD015530.pub2-BIB0127|cit127","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.1016\/S1473-3099(18)30601-7","article-title":"Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Mikulska","year":"2019","journal-title":"Lancet Infectious Diseases"},{"issue":"10","key":"10.1002\/14651858.CD015530.pub2-BIB0128|cit128","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"62","author":"Moher","year":"2009","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0129|cit129","unstructured":"Myeloproliferative neoplasms (MPN) and COVID-19 (MPN-COVID) https:\/\/clinicaltrials.gov\/study\/NCT04385160"},{"issue":"3","key":"10.1002\/14651858.CD015530.pub2-BIB0130|cit130","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/j.1469-0691.2005.01298.x","article-title":"Risk of bacteraemia and mortality in patients with haematological malignancies","volume":"12","author":"Norgaard","year":"2006","journal-title":"Clinical Microbiology and Infection"},{"issue":"12 Pt 2","key":"10.1002\/14651858.CD015530.pub2-BIB0131|cit131","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.7326\/0003-4819-142-12_part_2-200506211-00011","article-title":"Challenges in using nonrandomized studies in systematic reviews of treatment interventions","volume":"142","author":"Norris","year":"2005","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0132|cit132","doi-asserted-by":"publisher","first-page":"c3515","DOI":"10.1136\/bmj.c3515","article-title":"Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study","volume":"341","author":"N\u00fcesch","year":"2010","journal-title":"British Medical Journal"},{"issue":"210","key":"10.1002\/14651858.CD015530.pub2-BIB0133|cit133","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Systematic Reviews"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0134|cit134","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0135|cit135","unstructured":"Page MJ Higgins JP Sterne JAC Chapter 13: Assessing risk of bias due to missing evidence in a meta-analysis. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available at https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0136|cit136","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s41408-022-00684-8","article-title":"Effectiveness, immunogenicity, and safety of COVID-19 vaccines for individuals with hematological malignancies: a systematic review","volume":"12","author":"Piechotta","year":"2022","journal-title":"Blood Cancer Journal"},{"issue":"7","key":"10.1002\/14651858.CD015530.pub2-BIB0137|cit137","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clinical and Vaccine Immunology"},{"issue":"1026","key":"10.1002\/14651858.CD015530.pub2-BIB0138|cit138","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1016\/S0140-6736(20)32137-1","article-title":"SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates","volume":"396","author":"Poland","year":"2020","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0139|cit139","unstructured":"Reeves BC Deeks JJ Higgins JP Shea B Tugwell P Wells GA Chapter 24: Including non-randomized studies on intervention effects (last updated October 2019). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024 Available at https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0140|cit140","unstructured":"Review Manager (RevMan) The Cochrane Collaboration 2024"},{"issue":"6","key":"10.1002\/14651858.CD015530.pub2-BIB0141|cit141","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1093\/annonc\/mdy117","article-title":"Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors - guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO)","volume":"29","author":"Rieger","year":"2018","journal-title":"Annals of Oncology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0142|cit142","doi-asserted-by":"publisher","first-page":"951215","DOI":"10.3389\/fonc.2022.951215","article-title":"Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: systematic review and meta-analysis","volume":"12","author":"Rinaldi","year":"2022","journal-title":"Frontiers in Oncology"},{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0143|cit143","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40121-017-0146-1","article-title":"Infections in cancer patients with solid tumors: a review","volume":"6","author":"Rolston","year":"2017","journal-title":"Infectious Diseases and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD015530.pub2-BIB0144|cit144","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3390\/vaccines10020182","article-title":"Cellular immune response after vaccination in patients with cancer: review on past and present experiences","volume":"10","author":"R\u00fcthrich","year":"2022","journal-title":"Vaccines"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0145|cit145","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jclinepi.2019.10.014","article-title":"GRADE guidelines 26: informative statements to communicate the findings of systematic reviews of interventions","volume":"119","author":"Santesso","year":"2020","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0146|cit146","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jclinepi.2018.01.012","article-title":"GRADE guidelines: 18. How ROBINS-I and other tools to assess risk of bias in nonrandomized studies should be used to rate the certainty of a body of evidence","volume":"111","author":"Sch\u00fcnemann","year":"2019","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0147|cit147","unstructured":"Sch\u00fcnemann HJ Vist GE Higgins JPT Santesso N Deeks JJ Glasziou P Chapter 15: Interpreting results and drawing conclusions (last updated August 2023). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane, 2024 Available from https:\/\/training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0148|cit148","unstructured":"Sch\u00fcnemann HJ Higgins JP Vist GE Glasziou P Akl EA Skoetz N Chapter 14: Completing 'Summary of findings' tables and grading the certainty of the evidence (chapter last updated May 2025). In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.5.1. Cochrane, 2024 Available at https:\/\/training.cochrane.org\/handbook"},{"issue":"7","key":"10.1002\/14651858.CD015530.pub2-BIB0149|cit149","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00277-020-04107-1","article-title":"Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma","volume":"99","author":"Stemler","year":"2020","journal-title":"Annals of Hematology"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0150|cit150","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"7","key":"10.1002\/14651858.CD015530.pub2-BIB0152|cit152","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1182\/bloodadvances.2021006333","article-title":"Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis","volume":"6","author":"Teh","journal-title":"Blood Advances"},{"issue":"1","key":"10.1002\/14651858.CD015530.pub2-BIB0153|cit153","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/S1473-3099(23)00377-8","article-title":"Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients","volume":"24","author":"Teh","year":"2024","journal-title":"Lancet Infectious Diseases"},{"issue":"2","key":"10.1002\/14651858.CD015530.pub2-BIB0154|cit154","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.blre.2015.10.001","article-title":"Vaccinations in patients with hematological malignancies","volume":"30","author":"Tsigrelis","year":"2016","journal-title":"Blood Reviews"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0155|cit155","doi-asserted-by":"publisher","first-page":"328","DOI":"10.53854\/liim-2903-3","article-title":"Review of COVID-19 viral vector-based vaccines and COVID-19 variants","volume":"10","author":"Vanaparthy","year":"2021","journal-title":"Infezioni in Medicina"},{"issue":"5","key":"10.1002\/14651858.CD015530.pub2-BIB0156|cit156","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/jrsm.1425","article-title":"Development and validation of study filters for identifying controlled non-randomized studies in PubMed and Ovid MEDLINE","volume":"11","author":"Waffenschmidt","year":"2020","journal-title":"Research Synthesis Methods"},{"issue":"6","key":"10.1002\/14651858.CD015530.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/jamia\/ocx053","article-title":"Identifying reports of randomized controlled trials (RCTs) via a hybrid machine learning and crowdsourcing approach","volume":"24","author":"Wallace","year":"2017","journal-title":"Journal of the American Medical Informatics Association"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0158|cit158","unstructured":"World Health Organization Cancer https:\/\/www.who.int\/health-topics\/cancer"},{"key":"10.1002\/14651858.CD015530.pub2-BIB0159|cit159","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/9781118592168.ch29","volume-title":"The American Cancer Society's Oncology in Practice: Clinical Management","author":"Zeidner","year":"2018"},{"issue":"2","key":"10.1002\/14651858.CD015530.pub2-BIB0160|cit160","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s40121-021-00433-7","article-title":"Fatal infections among cancer patients: a population-based study in the United States","volume":"10","author":"Zheng","year":"2024","journal-title":"Infectious Diseases and Therapy"},{"issue":"2","key":"10.1002\/14651858.CD015530.pub2-BIB0161|cit161","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD015530","article-title":"Vaccines for the prevention of infections in adults with haematological malignancies","author":"Hirsch","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:37:30Z","timestamp":1788212250000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD015530.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Central Editorial Service","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":161,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd015530.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]}}}